Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023

Acer Therapeutics reports data from a survey of UCD healthcare providers show taste and odor are the most important attributes when considering treatment options and adherenceGENEVA, SWITZERLAND / ACCESSWIRE / March 22, 2023 / RELIEF THERAPEUTICS …